相关实验视频
Updated: May 8, 2026
08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
9.9K
人类单核RNA测序确定CD47为多克索鲁比诱导心肌病的治疗点
Zhen Guo1, Anahita Ataran1, Pan Ma1
1Washington University School of Medicine, St Louis, MO (Z.G., A.A., P.M., Y.W., H.H., C.V.R., L.P., O.R., M.M.C., M.S., S.K., A.S., M.O., A.L., Y.C., A.D., F.G., A.K., A.P., A.I., R.L., A.B.Z., A.K., J.S., M.S., K.S.R., S.D.P., C.B., J.D.S., K.J.L., A.J.).
Circulation
|August 14, 2025
概括
德克索鲁比辛诱导的心肌病 (DoxCM) 涉及增加CD47表达,阻碍心脏修复. 中和CD47保护心脏功能并减少纤维化,为DoxCM提供了新的治疗策略.
科学领域:
- 心脏病学
- 癌症学
- 免疫学
背景情况:
- 德克索鲁比心肌病 (DoxCM) 是一个主要的临床挑战,其机制尚不清楚.
- 确定DoxCM机制对于开发有效的治疗方法至关重要.
研究的目的:
- 调查DoxCM背后的分子机制
- 确定DoxCM的潜在治疗点.
主要方法:
- 从DoxCM患者,非缺血性心肌病患者和健康捐赠者的左心室肌肉组织单核RNA测序.
- 在人类和小鼠模型中进行免疫染,流细胞测量,抗体中和细胞耗尽研究.
- 转录变化的验证和体内机理学研究.
主要成果:
- 在DoxCM心脏中,POSTN+激活纤维细胞增加,细胞基因表达减少,CD47增加.
- 在人类DoxCM和小鼠乳腺癌模型中观察到POSTN+细胞和CD47的增加.
- CD47抗体中和可以预防和治疗多克索鲁比引起的心脏功能障碍和纤维化.
- 心脏巨细胞的消耗消除了CD47中和的心脏保护作用.
结论:
- CD47是DoxCM的疾病特异性标.
- CD47抗体中和是DoxCM中缓解心脏功能障碍的一个有希望的治疗策略.
相关概念视频
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...